Aug 26, 2019
The global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period
Jul 22, 2019
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress
Jun 18, 2019
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
Apr 11, 2019
FDA orders important safety labeling changes for Addyi
Mar 25, 2019
Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
Jan 28, 2019
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Oct 31, 2018
Potential Benefits of an Innovative New Device in Septic Shock
Aug 23, 2018
How Low is Too Low? Study Highlights Serious Risks for Intensive Blood Pressure Control
Aug 01, 2018
Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
May 17, 2018
Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
Mar 28, 2018
An Increase in Heart Rate as Blood Pressure Falls Could Be Early Sign of Neurological Disease
Mar 19, 2018
Edwards' Acumen Hypotension Prediction Index Launches In The U.S.
Feb 26, 2018
First Septic Shock Treatment Saves Child's Life at Levine Children's Hospital
Dec 21, 2017
FDA approves drug to treat dangerously low blood pressure